NSCLC Coverage From Every Angle

Recent News

Alectinib Versus Crizotinib in Advanced ALK-Positive Lung Cancer
Who Has Higher Incidence of Lung Cancer in United States: Young Women or Young Men?
Study Results Support Survival Benefit of Atezolizumab-Based Therapy in NSCLC
FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC
Long Noncoding RNAs as Potential Biomarkers in Non–Small Cell Lung Cancer
FDA Accepts Application for First-Line Combination Immunotherapy in Subgroup With NSCLC
ASCO 2018: Safety Analysis of First-Line Nivolumab Plus Ipilimumab for Advanced NSCLC
Projected Lung Cancer Rates in Patients Living With HIV
Combined Effects of FLT3 Ligand and Stereotactic Radiotherapy In Lung Cancer
ASCO 2018: Potential New Standard of Care in Pembrolizumab Combination for Advanced Squamous NSCLC
Expanded Indication for Pemetrexed in Combination Treatment of Metastatic NSCLC
ASCO 2018: Final Overall Survival Results With Dacomitinib vs. Gefitinib in NSCLC
ASCO 2018: Can Genome-Wide Sequencing Assays Detect Early-Stage Lung Cancer?
ASCO 2018: Addition of Immunotherapy to Chemotherapy for Advanced Squamous NSCLC
ASCO 2018: First-Line Pembrolizumab Versus Chemotherapy in Advanced Lung Cancer
Can Radiotherapy Improve Survival in Patients With Metastatic NSCLC?
FDA Accepts New Drug Application for Larotrectinib in Treatment of Certain Solid Tumors
Analysis of Circulating Tumor Cells in Patients With Early Lung Cancer
Second-Line TKI for Leptomeningeal Metastases in Lung Cancer
Atezolizumab Plus Bevacizumab and Chemotherapy in Nonsquamous Lung Cancer
Effect of Cardiac Doses on Survival in NSCLC After Accelerated Radiotherapy
ASCO 2018 Preview: Economic Impact of Genomic Testing Options in Metastatic NSCLC
ASCO 2018 Preview: Low Rates of Lung Cancer Screening Across the United States
Prophylactic Cranial Irradiation and Quality of Life for Patients With NSCLC
Response to Lorlatinib in ALK-Positive Lung Cancer
Pemetrexed Exposure and Adverse Events in NSCLC
FDA Grants Priority Review to Atezolizumab Combination for Metastatic Lung Cancer
AATS 2018: Staging-to-Surgery Time Interval in Stage I NSCLC
FDA Grants Priority Review to Supplemental Biologics License Application for Pembrolizumab in NSCLC
AACR 2018: Tumor Mutational Burden as Biomarker of Response to Immunotherapy in Lung Cancer
ESTRO 37: Concurrent Chemoradiotherapy in Older Patients With Lung Cancer
ELCC 2018: Patient-Reported Outcomes With Durvalumab From PACIFIC Trial
AACR 2018: Nivolumab/Ipilimumab Combination as First-Line Treatment in Advanced NSCLC
ELCC 2018: First-Line Osimertinib in Lung Cancer With Sensitizing EGFR Mutation
AACR 2018: Neoadjuvant Nivolumab for Resectable Lung Cancer
FDA Grants Approval to Osimertinib as First-Line Therapy for Metastatic NSCLC With EGFR Mutations
NCCN Annual Conference 2018: Debut of New Guidelines on Immunotherapy-Related Toxicity
ELCC 2018: Patient-Reported Outcomes With Alectinib Versus Crizotinib in ALK-Positive Lung Cancer
AACR 2018: First-Line Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer
ELCC 2018: Updated Survival Results With Atezolizumab in the POPLAR Trial
NCCN Annual Conference 2018: Updated Guidelines for NSCLC
FDA Accepts New Drug Application for Dacomitinib to Treat NSCLC With EGFR Mutations
Novel Tissue-Imaging Technology Used for Predicting Recurrence of Lung Cancer
Combination Therapy Plus Maintenance Bevacizumab in First-Line NSCLC
ASCO Endorses ASTRO Guidelines on Stereotactic Body Radiotherapy for NSCLC
Novel Interventional Pulmonology Procedures for Lung Cancer Diagnosis and Treatment
Proton vs. Photon Therapy for Patients With Lung Cancer
Preoperative Exercise and Postoperative Wellness for Patients With Lung Cancer
Interstitial Pneumonitis and Nivolumab Combination Therapy for Lung Cancer
FDA Expands Approval of Durvalumab in Advanced Unresectable Lung Cancer
FDA Grants Priority Review to Lorlatinib in ALK-Positive Lung Cancer
Benefits of Newer Risk-Based Criteria for Lung Cancer Screening
Benefit of Sequential Chemotherapy Followed by Postoperative Radiotherapy for Patients With Lung Cancer
Updated Guidelines for Molecular Testing and Targeted Therapies in Lung Cancer
ASCO-SITC 2018: Study Sheds Light on Immune Microenvironment of Lung Tumors
Smoking History and Molecular Testing for Lung Adenocarcinoma
Path and Evolution of Drug-Resistant Clones in Lung Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.